Patents Examined by Erich A. Leeser
  • Patent number: 12291538
    Abstract: The disclosure provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein W1, W2, Y, Z, M, L, Cy, Cz, R1, R2, R3, R4, R2a, Ry, Rz, and the subscripts m, n, q, and r are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.
    Type: Grant
    Filed: May 3, 2023
    Date of Patent: May 6, 2025
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Indu Bharathan, Symon Gathiaka, Yongxin Han, Xiaoshen Ma, Ryan D. Otte, David L. Sloman, Thomas H. Graham, Timothy Henderson, Elisabeth Hennessy, Anandan Palani
  • Patent number: 12286411
    Abstract: The invention relates to an indane compound according to Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, L, n and p are as defined herein. The compounds are useful for treating antibacterial infection either as stand-alone antibiotics, or in combination with further antibiotics.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: April 29, 2025
    Assignee: Antabio SAS
    Inventors: Simon Leiris, David Thomas Davies, Martin Everett, Nicolas Sprynski, Lilha Beyria, Thomas David Pallin, Andrew Peter Cridland, Toby Jonathan Blench, Richard Leonard Elliott, David Edward Clark
  • Patent number: 12263190
    Abstract: The present disclosure relates in some aspects to methods, compositions and uses involving immunotherapies, such as adoptive cell therapy, e.g., T cell therapy, and an immunomodulatory compound, such as a structural or functional analog or derivative of thalidomide and/or an inhibitor of E3-ubiquitin ligase. The provided methods, compositions and uses include those for combination therapies involving the administration or use of one or more immunomodulatory compounds in conjunction with a T cell therapy, such as a genetically engineered T cell therapy involving cells engineered with a recombinant receptor, such as chimeric antigen receptor (CAR)-expressing T cells. Also provided are compositions, methods of administration to subjects, articles of manufacture and kits for use in the methods.
    Type: Grant
    Filed: November 7, 2019
    Date of Patent: April 1, 2025
    Assignee: Juno Therapeutics, Inc.
    Inventors: Jens Hasskarl, Stanley R. Frankel, Michael Ports, Michael Pourdehnad, Heidi Jessup, Yue Jiang, Jim Shi Xiang Qin, Neha Soni, Melissa Works
  • Patent number: 12257215
    Abstract: The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng·h/mL, (ii) a Cmax no more than 40 ng/mL, or (iii) both.
    Type: Grant
    Filed: May 24, 2024
    Date of Patent: March 25, 2025
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Uchenna H. Iloeje, Abraham J. Langseth, Todd Webster Shearer
  • Patent number: 12247010
    Abstract: Provided herein are compounds, pharmaceutical compositions, and methods of treatment for various diseases, such as cancer. In one aspect, the method comprises the treatment of brain cancers or metastatic cancers that spread to the brain.
    Type: Grant
    Filed: April 29, 2021
    Date of Patent: March 11, 2025
    Inventors: Tom Lin, Cheng-Chi Irene Wang, Jason Olejniczak, Jessica Crisp, Richard Truong
  • Patent number: 12240851
    Abstract: Novel pyrido[3?,4?:4,5]pyrrolo[3,2-c]naphthyridine compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrido[3?,4?:4,5]pyrrolo[3,2-c]naphthyridine compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.
    Type: Grant
    Filed: December 5, 2023
    Date of Patent: March 4, 2025
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Christophe Tratrat, Michelyne Haroun
  • Patent number: 12240833
    Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.
    Type: Grant
    Filed: May 27, 2022
    Date of Patent: March 4, 2025
    Assignee: EDGEWISE THERAPEUTICS, INC.
    Inventors: Kevin Hunt, Kevin Koch, Alan Russell, Stephen Schlachter, Paul Winship, Grace Uzoho, Chris Steele
  • Patent number: 12234230
    Abstract: Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.
    Type: Grant
    Filed: June 29, 2022
    Date of Patent: February 25, 2025
    Assignee: NURIX THERAPEUTICS, INC.
    Inventors: Arthur T. Sands, Neil F. Bence, Christoph W. Zapf, Frederick Cohen, Chenbo Wang, Thomas Cummins, Hiroko Tanaka, Hunter Shunatona, Mario Cardozo, Dahlia Weiss, Jennifa Gosling
  • Patent number: 12220390
    Abstract: The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng·h/mL, (ii) a Cmax no more than 40 ng/mL, or (iii) both.
    Type: Grant
    Filed: May 24, 2024
    Date of Patent: February 11, 2025
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Uchenna H. Iloeje, Abraham J. Langseth, Todd Webster Shearer
  • Patent number: 12221449
    Abstract: Provided is a new compound capable of effectively inhibiting ATX. The compound is represented by formula I, or the compound is a tautomer, a stereoisomer, a hydrate, a solvate, a salt, or a prodrug of the compound represented by formula I. In formula (I), R1 and R2 are independently selected from —H or —CH3, provided that: R1 and R2 are not —H at the same time or are not —CH3 at the same time.
    Type: Grant
    Filed: January 22, 2020
    Date of Patent: February 11, 2025
    Assignee: WUHAN HUMANWELL INNOVATIVE DRUG RESEARCH AND DEVELOPMENT CENTER LIMITED COMPANY
    Inventors: Xuejun Zhang, Dabing Ye, Lie Li, Jie Shen, Xiaohua Ding, Hongna Sun, Zhe Liu, Yang Zang, Yonggang Wei
  • Patent number: 12215086
    Abstract: This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including heterocyclic anilide rings and their synthetic precursors. R-isomers, and non-hydroxylated and/or non-chiral propenamides, and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic to or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.
    Type: Grant
    Filed: January 24, 2022
    Date of Patent: February 4, 2025
    Assignee: University of Tennessee Research Foundation
    Inventors: Ramesh Narayanan, Duane D. Miller, Thamarai Ponnusamy, Dong-Jin Hwang, Yali He
  • Patent number: 12213957
    Abstract: The present invention relates to the use of aminoacetonitrile derivatives (AADs) in the treatment of cancer and mTOR (mammalian Target of Rapamycin) pathway related diseases. In particular it relates to the use of AADs administered at particular dose amounts in order to achieve therapeutic effects.
    Type: Grant
    Filed: May 11, 2021
    Date of Patent: February 4, 2025
    Assignee: PITNEY PHARMACEUTICALS PTY LIMITED
    Inventors: Roger Aston, Richard Mollard
  • Patent number: 12180217
    Abstract: Compounds and methods of using said compounds, singly or in combination with additional agents, and salts or pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
    Type: Grant
    Filed: March 11, 2024
    Date of Patent: December 31, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Mark J. Bartlett, Daniel H. Byun, Yifan Deng, Jennifer L. Cosman Ellis, Rao V. Kalla, Richard L Mackman, Dustin S. Siegel, Xianhuang Zeng
  • Patent number: 12171756
    Abstract: The present invention provides compounds of Formula (I): wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).
    Type: Grant
    Filed: April 28, 2022
    Date of Patent: December 24, 2024
    Assignee: INNATE TUMOR IMMUNITY, INC.
    Inventors: Daniel O'Malley, Ashvinikumar V. Gavai, Patrice Gill, Christine M. Tarby, Scott Hunter Watterson, Hua Gong, David K. Williams, Shomir Ghosh, William R. Roush
  • Patent number: 12173002
    Abstract: Compounds that inhibit Protein Arginine N-Methyl Transferase 5(PRMT5) activity, as well as method for their preparation and use are provided. Specifically, compounds of Formula (I) and pharmaceutically acceptable salts, hydrates and solvates, as well as method for their preparation and use are provided.
    Type: Grant
    Filed: February 9, 2024
    Date of Patent: December 24, 2024
    Assignee: SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED
    Inventors: Bing Yao, Xiaohui Gu
  • Patent number: 12152030
    Abstract: Provided is a polycyclic compound inhibiting MNK1 and MNK2. Specifically, provided is a compound represented by formula (I), or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein the definition of each group is as described in the description. These compounds can be used for preparing pharmaceutical compositions for the treatment of diseases or disorders related to MNK activity or expression level.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: November 26, 2024
    Assignee: NOVOSTAR PHARMACEUTICALS, LTD.
    Inventor: Bing Li
  • Patent number: 12139505
    Abstract: Lanthionine ketimine phosphonate (LK-P), lanthionine ketimine ester phosphonate (LKE-P), other lanthionine ketimine, lanthionine ketimine phosphonate, and lanthionine ketimine ester derivatives, methods of making and using the same, and methods of treatments are described.
    Type: Grant
    Filed: January 4, 2021
    Date of Patent: November 12, 2024
    Assignees: The University of Toledo, Washington State University
    Inventors: Kenneth Hensley, Travis Denton
  • Patent number: 12133852
    Abstract: The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral infection, alcoholism, alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), obesity/weight gain, anxiety, depression, post-traumatic stress disorder, inflammatory/autoimmune conditions and cancer, including metastatic cancer, advanced cancer, and drug resistant cancer of various types.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: November 5, 2024
    Assignee: EpiVario, Inc.
    Inventors: Philippe Nakache, Omri Erez, Simone Botti, Andreas Goutopoulos
  • Patent number: 12129242
    Abstract: The present invention provides novel substituted benzimidazole derivatives used as DAAO inhibitors and for treatment and/or prevention of neurological disorders.
    Type: Grant
    Filed: March 30, 2022
    Date of Patent: October 29, 2024
    Assignees: NATIONAL TAIWAN UNIVERSITY, NATIONAL YANG MING CHIAO TUNG UNIVERSITY, NATIONAL HEALTH RESEARCH INSTITUTES
    Inventors: Yufeng Jane Tseng, Yu-Li Liu, Chung-Ming Sun, Wen-Sung Lai, Chih-Min Liu, Hai-Gwo Hwu
  • Patent number: 12122791
    Abstract: The present invention relates to a process for the preparation of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives useful as pharmaceutically active compounds.
    Type: Grant
    Filed: June 16, 2022
    Date of Patent: October 22, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jean-Michel Adam, Serena Maria Fantasia, Daniel Vincent Fishlock, Fabienne Hoffmann-Emery, Gerard Moine, Christophe Pfleger, Christian Moessner